Source: SUNY Downstate Medical Center
Date: November 30, 2006
Summary:
Researchers at SUNY Downstate Medical Center have developed a substance that inhibits the progress of multiple sclerosis (MS) in an animal model. The agent, a novel calpain inhibitor, can be administered orally. In a paper published in the Journal of Neuroimmunology,researchers described the use of the calpain inhibitor for the treatment of a mouse model of MS. Whether administered by injection or by mouth, the inhibitor produced an almost complete cessation of the disease's progress.
Thursday, November 30, 2006
"Cancer prognosis gene" found to control the fate of breast cells
Source: University of California - San Francisco
Date: November 30, 2006
Summary:
Scientists have discovered an unsuspected role for a gene known to be one of the best predictors of human breast cancer outcome. The scientists hope that further investigation of the precise role of the gene in breast cancer can identify new ways of understanding, diagnosing and treating the disease.
Date: November 30, 2006
Summary:
Scientists have discovered an unsuspected role for a gene known to be one of the best predictors of human breast cancer outcome. The scientists hope that further investigation of the precise role of the gene in breast cancer can identify new ways of understanding, diagnosing and treating the disease.
Stem cell trial may bring end of back pain for millions
Source: Evening Standard
Date: 30 November 2006
Summary:
Scientists at the University of Manchester, UK, reported the development of a radical new stem cell treatment that could totally regenerate damaged tissues and bring relief to millions of back pain sufferers.
Date: 30 November 2006
Summary:
Scientists at the University of Manchester, UK, reported the development of a radical new stem cell treatment that could totally regenerate damaged tissues and bring relief to millions of back pain sufferers.
Adult Stem Cells Proving Worth In Spinal Healing
Source: The Louisville Channel
POSTED: 3:10 pm EST November 30, 2006
UPDATED: 3:27 pm EST November 30, 2006
Summary:
A new groundbreaking study using stem cells from nasal passages to help rebuild damaged spinal cord tissue conducted at the University of Louisville’s School of Medicine may lead to a new therapy to reverse the disabling effects of spinal cord injuries.
POSTED: 3:10 pm EST November 30, 2006
UPDATED: 3:27 pm EST November 30, 2006
Summary:
A new groundbreaking study using stem cells from nasal passages to help rebuild damaged spinal cord tissue conducted at the University of Louisville’s School of Medicine may lead to a new therapy to reverse the disabling effects of spinal cord injuries.
Finding Offers New Path For Treatment Of Diabetes
Source: New York University
Date: November 30, 2006
Summary:
Researchers at New York University and the Scripps Research Institute have discovered a new enzyme, GAPDH, which regulates insulin pathways--a finding that offers a new direction for the treatment of diabetes. The research is reported in the most recent issue of the journal Nature Chemical Biology. The new-found enzyme provides another strategy to treat the disease.
Date: November 30, 2006
Summary:
Researchers at New York University and the Scripps Research Institute have discovered a new enzyme, GAPDH, which regulates insulin pathways--a finding that offers a new direction for the treatment of diabetes. The research is reported in the most recent issue of the journal Nature Chemical Biology. The new-found enzyme provides another strategy to treat the disease.
One-off treatment to stop back pain -- Using patients' own stem cells
Source: University of Manchester
Date: November 30, 2006
Summary:
A University of Manchester researcher has developed a treatment for lower back pain using the patient’s own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.
Date: November 30, 2006
Summary:
A University of Manchester researcher has developed a treatment for lower back pain using the patient’s own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.
Stem cell cure hope for back pain
Source: BBC NEWS
Posted: 30 November 2006, 18:04:20 GMT
Summary:
Researchers from the University of Manchester are working to develop a new treatment for chronic back pain that uses a patient's own stem cells to rebuild the soft shock-absorbing discs which separate the vertebrae in the spine. The group hopes their treatment will be available within three years.
Posted: 30 November 2006, 18:04:20 GMT
Summary:
Researchers from the University of Manchester are working to develop a new treatment for chronic back pain that uses a patient's own stem cells to rebuild the soft shock-absorbing discs which separate the vertebrae in the spine. The group hopes their treatment will be available within three years.
Wednesday, November 29, 2006
RejuvaCell's Breakthrough Stem Cell Therapy Demonstrates Potential to Revolutionize Treatment for Type-2 Diabetes
Source: RejuvaCell Inc.
Posted: November 29, 2006
Summary:
RejuvaCell Inc., a global leader in adult stem cell therapy for intractable Heart and Vascular diseases, achieves extraordinary advances in the treatment of type-2 diabetes. Over 200 patients treated to date, with 85% of 100 Patients at one year on, maintain significant improvement.
Posted: November 29, 2006
Summary:
RejuvaCell Inc., a global leader in adult stem cell therapy for intractable Heart and Vascular diseases, achieves extraordinary advances in the treatment of type-2 diabetes. Over 200 patients treated to date, with 85% of 100 Patients at one year on, maintain significant improvement.
Stem Cell Therapy International Reports the Successful Treatment of a Stroke Patient With Their Proprietary Stem Cell Transplantation Therapy
Source: Stem Cell Therapy International, Inc.
Posted: November 29, 2006 9:15 am ET
Summary:
TAMPA, FL -- Stem Cell Therapy International, Inc. (PINKSHEETS: SCII), a company in the field of research and development of stem cell transplantation therapy and regenerative medicine, announced the successful treatment of a stroke patient from the United States with its stem cell transplantation therapy protocol conducted at one of their affiliate clinics in Kiev, Ukraine.
Posted: November 29, 2006 9:15 am ET
Summary:
TAMPA, FL -- Stem Cell Therapy International, Inc. (PINKSHEETS: SCII), a company in the field of research and development of stem cell transplantation therapy and regenerative medicine, announced the successful treatment of a stroke patient from the United States with its stem cell transplantation therapy protocol conducted at one of their affiliate clinics in Kiev, Ukraine.
Tuesday, November 28, 2006
Master Gene Makes Skeletal Progenitor Cells Differentiate Into Cartilage Cells
Source: Baylor College of Medicine
Date: November 28, 2006
Summary:
Skeletal progenitor cells differentiate into cartilage cells when one master gene actually suppresses the action of another, said Baylor College of Medicine researchers in a report that appears online in the journal Proceedings of the National Academy of Sciences.
Date: November 28, 2006
Summary:
Skeletal progenitor cells differentiate into cartilage cells when one master gene actually suppresses the action of another, said Baylor College of Medicine researchers in a report that appears online in the journal Proceedings of the National Academy of Sciences.
Oncologists study colon cancer stem cells
Source: United Press International
Date: November 28, 2006
Summary:
Canadian and Italian scientists have identified and characterized a type of colon cancer cell capable of causing tumors in mice.
Date: November 28, 2006
Summary:
Canadian and Italian scientists have identified and characterized a type of colon cancer cell capable of causing tumors in mice.
Journal: Stem cell safeguards needed
Source: Associated Press
Posted: November 28, 2006, 11:14 a.m. PT
Summary:
The journal Science plans to adopt some stricter safeguards against fraud, in wake of a headline-grabbing South Korean cloning sham exposed a year ago.
Posted: November 28, 2006, 11:14 a.m. PT
Summary:
The journal Science plans to adopt some stricter safeguards against fraud, in wake of a headline-grabbing South Korean cloning sham exposed a year ago.
Revealed: how to fix a broken heart
Source: Daily Telegraph
Posted: November 28, 2006
Summary:
British scientists discovered that a specific protein is required for blood vessel and heart tissue development. By fully reactiviating this protein to guide progenitor cells from the rind of the heart to form new blood vessels within, it could be possible to restore blood flow to muscle that has been starved of oxygen. The protein could also help to solve a mystery about how experimental stem cell treatments work. Animal tests show that stem cells – bone marrow cells with the potential to turn into many types – can be infused into a heart after an attack and repair and regenerate damaged heart muscle, improving heart function and circulation.
Posted: November 28, 2006
Summary:
British scientists discovered that a specific protein is required for blood vessel and heart tissue development. By fully reactiviating this protein to guide progenitor cells from the rind of the heart to form new blood vessels within, it could be possible to restore blood flow to muscle that has been starved of oxygen. The protein could also help to solve a mystery about how experimental stem cell treatments work. Animal tests show that stem cells – bone marrow cells with the potential to turn into many types – can be infused into a heart after an attack and repair and regenerate damaged heart muscle, improving heart function and circulation.
Monday, November 27, 2006
New data from NIH lab confirms protocol to reverse type 1 diabetes in mice
Source: Massachusetts General Hospital
Date: November 27, 2006
Summary:
New data published in the Nov. 24 issue of Science provide further support for a protocol to reverse type 1 diabetes in mice and new evidence that adult precursor cells from the spleen can contribute to the regeneration of beta cells. In 2001 and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the efficacy of a protocol to reverse of type 1 diabetes in diabetic mice. Three studies from other institutions published in the March 24, 2006 issue of Science confirmed that the MGH-developed protocol can reverse the underlying disease but were inconclusive on the role of spleen cells in the recovery of insulin-producing pancreatic islets. The new data from a study performed at the National Institutes of Health (NIH), published as a technical comment, provides additional confirmation of the ability to reverse type 1 diabetes and on the role of the spleen cells in islet regeneration.
Date: November 27, 2006
Summary:
New data published in the Nov. 24 issue of Science provide further support for a protocol to reverse type 1 diabetes in mice and new evidence that adult precursor cells from the spleen can contribute to the regeneration of beta cells. In 2001 and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the efficacy of a protocol to reverse of type 1 diabetes in diabetic mice. Three studies from other institutions published in the March 24, 2006 issue of Science confirmed that the MGH-developed protocol can reverse the underlying disease but were inconclusive on the role of spleen cells in the recovery of insulin-producing pancreatic islets. The new data from a study performed at the National Institutes of Health (NIH), published as a technical comment, provides additional confirmation of the ability to reverse type 1 diabetes and on the role of the spleen cells in islet regeneration.
Parkinson's Mutation Stunts Neurons
Source: Cell Press
Date: November 27, 2006
Summary:
Mutations in a key brain protein known to underlie a form of Parkinson's disease (PD) wreaks its damage by stunting the normal growth and branching of neurons, researchers have found. They have pinpointed the malfunction of the protein made by mutant forms of the gene called LRRK2 and how it affects neurons, ultimately leading to their death. The loss of dopamine-producing neurons is central to the pathology of PD, and loss of connections among such neurons is an early feature of the PD disease process.
Date: November 27, 2006
Summary:
Mutations in a key brain protein known to underlie a form of Parkinson's disease (PD) wreaks its damage by stunting the normal growth and branching of neurons, researchers have found. They have pinpointed the malfunction of the protein made by mutant forms of the gene called LRRK2 and how it affects neurons, ultimately leading to their death. The loss of dopamine-producing neurons is central to the pathology of PD, and loss of connections among such neurons is an early feature of the PD disease process.
New Data Confirms Protocol To Reverse Type 1 Diabetes In Mice
Source: Massachusetts General Hospital
Date: November 27, 2006
Summary:
New data published in the Nov. 24 issue of Science provide further support for a protocol to reverse type 1 diabetes in mice and new evidence that adult precursor cells from the spleen can contribute to the regeneration of beta cells. In 2001 and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the efficacy of a protocol to reverse of type 1 diabetes in diabetic mice. Three studies from other institutions published in the March 24, 2006 issue of Science confirmed that the MGH-developed protocol can reverse the underlying disease but were inconclusive on the role of spleen cells in the recovery of insulin-producing pancreatic islets. The new data from a study performed at the National Institutes of Health (NIH), published as a technical comment, provides additional confirmation of the ability to reverse type 1 diabetes and on the role of the spleen cells in islet regeneration.
Date: November 27, 2006
Summary:
New data published in the Nov. 24 issue of Science provide further support for a protocol to reverse type 1 diabetes in mice and new evidence that adult precursor cells from the spleen can contribute to the regeneration of beta cells. In 2001 and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the efficacy of a protocol to reverse of type 1 diabetes in diabetic mice. Three studies from other institutions published in the March 24, 2006 issue of Science confirmed that the MGH-developed protocol can reverse the underlying disease but were inconclusive on the role of spleen cells in the recovery of insulin-producing pancreatic islets. The new data from a study performed at the National Institutes of Health (NIH), published as a technical comment, provides additional confirmation of the ability to reverse type 1 diabetes and on the role of the spleen cells in islet regeneration.
Some Stem Cell Transplant Recipients Face Long-Term Risk: Leukemia patients almost twice as likely to develop a solid cancer within 10 years
Source: HealthDay News
Date: November 27, 2006
Summary:
A new study by researchers from the University of British Columbia and the BC Cancer Agency. has found that Patients with diseases such as leukemia or myelodysplastic syndrome who receive a hematopoietic stem cell transplant (HSCT) have an increased long-term risk of developing a cancer.
Date: November 27, 2006
Summary:
A new study by researchers from the University of British Columbia and the BC Cancer Agency. has found that Patients with diseases such as leukemia or myelodysplastic syndrome who receive a hematopoietic stem cell transplant (HSCT) have an increased long-term risk of developing a cancer.
Stem cell transplant cancer risks studied
Source: United Press International
Date: November 27, 2006
Summary:
Canadian scientists report hematopoietic, or bone marrow, stem cell transplant recipients face a significant long-term risk of developing a second cancer.
Date: November 27, 2006
Summary:
Canadian scientists report hematopoietic, or bone marrow, stem cell transplant recipients face a significant long-term risk of developing a second cancer.
Stem cell transplants from women raise cancer risk
Source: NewScientist.com news service
Posted: 05:00 27 November 2006
Summary:
People who receive stem cell transplants for diseases such as leukaemia appear to face a higher risk of developing secondary cancers, especially if the cells come from a female donor, according to a preliminary study. The scientists behind the new report caution that future stem cell treatments for ailments such as spinal cord injury and heart failure might also carry a cancer risk. However, experts point out that the study is far from conclusive and more work needs to be done to confirm a link between stem cell transplants and tumours.
Posted: 05:00 27 November 2006
Summary:
People who receive stem cell transplants for diseases such as leukaemia appear to face a higher risk of developing secondary cancers, especially if the cells come from a female donor, according to a preliminary study. The scientists behind the new report caution that future stem cell treatments for ailments such as spinal cord injury and heart failure might also carry a cancer risk. However, experts point out that the study is far from conclusive and more work needs to be done to confirm a link between stem cell transplants and tumours.
Sunday, November 26, 2006
Long-term cancer risk follows stem cell transplant recipients
Source: John Wiley & Sons, Inc.
Date: November 27, 2006
Summary:
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study. Published in the January 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population.
Date: November 27, 2006
Summary:
Hematopoietic stem cell transplant (HSCT) recipients face a significant long-term risk for developing a second cancer, particularly if they were older at the time of transplant or received stem cells from a female donor, according to a new study. Published in the January 1, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that within 10 years of an allogeneic HSCT, the relative risk of a second, solid cancer is almost twice that of the general population.
Subscribe to:
Posts (Atom)